Chiral Technologies Europe (CTE), a wholly owned subsidiary of DAICEL Chemical Industries, Ltd, announced the acquisition of ChromTech Ltd, of Congleton, U.K.
According to the company, the two companies’ combined product lines of enantioselective chromatography columns will provide a powerful solutions portfolio for developing assays for new and existing chiral entities by pharmaceutical and biopharmaceutical companies.
Commenting on the acquisition, CTE’s President Dieter Heckmann stated, “We are extremely pleased with ChromTech’s decision to become part of Chiral Technologies. ChromTech’s specialty line of protein-based columns adds a complementary product range to our Daicel polysaccharide-based products. The company’s expertise enables the continued expansion of our core capabilities in separation science and will provide us significant access to new opportunities in enantioselective chromatography.”
ChromTech’s founder and Managing Director Prof. Jörgen Hermansson stated, “We are very excited to become part of Chiral Technologies Europe. Powered with the strength and reputation of Daicel Industries, Chiral Technologies has become the premier supplier of high quality separation solutions of chiral compounds worldwide. We are proud to add our chirality tools to those of Chiral Technologies.”